NEW YORK, NY, January 08, 2026 /24-7PressRelease/ -- As immunotherapy continues to grow, researchers face a familiar challenge: many traditional tumor models do not fully reproduce immune responses, making it difficult to predict how a treatment will behave in preclinical testing. To help solve this problem, Alfa Cytology has launched the Next-Gen PBMC-humanized PDX platform. The platform provides a system that shows tumor and immune interactions more clearly and allows studies that better reflect immune-related treatment effects in preclinical settings.

Alfa Cytology has been developing in vitro and in vivo models of cancer for years, including cell line-derived models, 3D cultures, cancer type-specific panels, and multiple animal models. These tools are used in drug testing, studying how treatments work, validating targets, assessing drug distribution, and tracking resistance. Combined, they assist research teams in starting with lab experiments and then confirming results in animal models, giving a clearer view of treatment effects at each stage before moving toward further preclinical studies.

Traditional PDX models often fall short when immune activity is important, limiting their usefulness in immuno-oncology research. PrimePDX™ solves this by adding human PBMCs to create a functional immune system in mice. Small tumor fragments or early-passage tissues (P2–P5) are used to keep tumor structures intact and maintain diversity. Human CAFs can also be added to reproduce key features of the tumor microenvironment when needed. Tumor growth and immune reconstitution are monitored throughout the study, and optional IVIS imaging allows non-invasive tracking of tumor progression.

PrimePDX™ is suitable for testing checkpoint inhibitors, antibody therapies, cell therapies, cancer vaccines, and other immune-based treatments. When used together with Alfa Cytology's in vitro platforms, researchers can first screen treatments in the lab, then confirm effects in animal models, and finally evaluate whether effects observed in lab studies are consistent in animal models. This process helps teams track tumor-immune interactions and assess the potential of therapeutic candidates and combination strategies in preclinical research.

"In immuno-oncology research, having models that accurately represent immune responses is crucial," said a project lead at Alfa Cytology. "PrimePDX™ provides a controlled setting to observe tumor growth, immune cell behavior, and treatment effects. This helps scientists to improve study designs, evaluate combination approaches, and make more confident decisions before further preclinical testing."

About Alfa Cytology
Alfa Cytology provides a wide range of cancer research models and preclinical testing services, covering in vitro platforms, in vivo systems, and functional testing technologies. These resources promote tumor biology studies, drug evaluation, and immunotherapy research, delivering steady and reliable results. The company's technical team continues to develop new models and testing options, supporting the design of studies for various cancer types, research needs, and emerging scientific challenges.

# # #